BACKGROUND: The simultaneous assessment of high-sensitivity cardiac troponin T (hscTnT) and NT-proBNP for predicting death in stable coronary artery disease (CAD) has yet not been examined. We investigated the additional contribution of hscTnT to the risk of mortality prediction of NT-proBNP in patients with stable CAD. METHODS: We studied 1469 patients with stable CAD enrolled in the Ludwigshafen Risk and Cardiovascular Health Study (LURIC). hscTnT and NT-proBNP were measured in baseline samples using immunoassays (Roche Diagnostics, Germany). RESULTS: Thirty-five percent (n=525) of the patients died during a median follow-up of 7 and a half years. In total 59.0% of the non-survivors and 25.2% of the survivors exhibited concentrations of hscTnT≥14 ng/L. Logistic regression analysis identified hscTnT and NT-proBNP as independent risk markers for short-term (1-year follow-up) and long-term (9-years follow-up) mortality. ROC curve analysis determined optimal univariate cut-offs at 14 ng/L and 443 µg/L for hscTnT (AUC 0.725, p<0.0001) and NT-proBNP (AUC 0.742, p<0.0001), respectively. Kaplan-Meier survival analysis based on optimized cut-offs for the simultaneous determination of both biomarkers confirmed the usefulness of additive hscTnT especially in prediction of short-term mortality. The prognostic benefit of the combined assessment of hscTnT and NT-proBNP could be confirmed by a significantly increased reclassification index (NRI) of 24.2%. CONCLUSIONS: The majority of non-survivors exhibited increased hscTnT concentrations above 14 ng/L. The simultaneous determination of NT-proBNP and hscTnT was superior for risk stratification compared to determining either marker alone. Especially the prediction of the clinically important 1-year mortality was significantly improved by addition of hscTnT to NT-proBNP.
BACKGROUND: The simultaneous assessment of high-sensitivity cardiac troponin T (hscTnT) and NT-proBNP for predicting death in stable coronary artery disease (CAD) has yet not been examined. We investigated the additional contribution of hscTnT to the risk of mortality prediction of NT-proBNP in patients with stable CAD. METHODS: We studied 1469 patients with stable CAD enrolled in the Ludwigshafen Risk and Cardiovascular Health Study (LURIC). hscTnT and NT-proBNP were measured in baseline samples using immunoassays (Roche Diagnostics, Germany). RESULTS: Thirty-five percent (n=525) of the patients died during a median follow-up of 7 and a half years. In total 59.0% of the non-survivors and 25.2% of the survivors exhibited concentrations of hscTnT≥14 ng/L. Logistic regression analysis identified hscTnT and NT-proBNP as independent risk markers for short-term (1-year follow-up) and long-term (9-years follow-up) mortality. ROC curve analysis determined optimal univariate cut-offs at 14 ng/L and 443 µg/L for hscTnT (AUC 0.725, p<0.0001) and NT-proBNP (AUC 0.742, p<0.0001), respectively. Kaplan-Meier survival analysis based on optimized cut-offs for the simultaneous determination of both biomarkers confirmed the usefulness of additive hscTnT especially in prediction of short-term mortality. The prognostic benefit of the combined assessment of hscTnT and NT-proBNP could be confirmed by a significantly increased reclassification index (NRI) of 24.2%. CONCLUSIONS: The majority of non-survivors exhibited increased hscTnT concentrations above 14 ng/L. The simultaneous determination of NT-proBNP and hscTnT was superior for risk stratification compared to determining either marker alone. Especially the prediction of the clinically important 1-year mortality was significantly improved by addition of hscTnT to NT-proBNP.
Authors: Carlos Alexandre Wainrober Segre; Whady Hueb; Rosa Maria Rahmi Garcia; Paulo Cury Rezende; Desiderio Favarato; Celia Maria Cassaro Strunz; Marília da Costa Oliveira Sprandel; Alessandra Roggério; Ana Luiza de Oliveira Carvalho; Raul Cavalcante Maranhão; José Antonio Franchini Ramires; Roberto Kalil Filho Journal: BMC Cardiovasc Disord Date: 2015-07-21 Impact factor: 2.298
Authors: Rohit M Oemrawsingh; K Martijn Akkerhuis; Victor A Umans; Bas Kietselaer; Carl Schotborgh; Eelko Ronner; Timo Lenderink; Anho Liem; David Haitsma; Pim van der Harst; Folkert W Asselbergs; Arthur Maas; Anton J Oude Ophuis; Ben Ilmer; Rene Dijkgraaf; Robbert-Jan de Winter; S Hong Kie The; Alexander J Wardeh; Walter Hermans; Etienne Cramer; Ron H van Schaik; Imo E Hoefer; Pieter A Doevendans; Maarten L Simoons; Eric Boersma Journal: BMJ Open Date: 2016-12-23 Impact factor: 2.692
Authors: Wojciech Szczeklik; Marek Krzanowski; Paweł Maga; Łukasz Partyka; Jolanta Kościelniak; Paweł Kaczmarczyk; Mikołaj Maga; Patrycja Pieczka; Anna Suska; Agnieszka Wachsmann; Jacek Górka; Bruce Biccard; P J Devereaux Journal: Clin Res Cardiol Date: 2017-11-24 Impact factor: 5.460
Authors: Benjamin Bay; Alina Goßling; Christopher M Blaum; Friederike Kroeger; Luise Koppe; Thiess Lorenz; Lukas Koester; Peter Clemmensen; Dirk Westermann; Paulus Kirchhof; Stefan Blankenberg; Tanja Zeller; Moritz Seiffert; Christoph Waldeyer; Fabian J Brunner Journal: J Am Heart Assoc Date: 2022-07-19 Impact factor: 6.106
Authors: Jeffrey Netto; Andrej Teren; Ralph Burkhardt; Anja Willenberg; Frank Beutner; Sylvia Henger; Gerhard Schuler; Holger Thiele; Berend Isermann; Joachim Thiery; Markus Scholz; Thorsten Kaiser Journal: Nutrients Date: 2022-08-20 Impact factor: 6.706
Authors: Moritz Biener; Evangelos Giannitsis; Manuel Kuhner; Thomas Zelniker; Matthias Mueller-Hennessen; Mehrshad Vafaie; Kiril M Stoyanov; Franz-Josef Neumann; Hugo A Katus; Willibald Hochholzer; Christian Marc Valina Journal: Open Heart Date: 2018-04-25